Free Download of The Capitol Forum's Report: " Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain "
In 2020, I wrote a blog post entitled " It ' s the Rx rebates, stupid! " (seehttps://blog.sstrumello.com/2020/09/its-rx-rebates-stupid.html for the post) in which I revealed the reason everyone was overpaying for insulin was because of rebating paid by insulin-makers to secure PBM formulary placement. Novo Nordisk revealed to its investors that it was spending 74% of its gross U.S. sales in the form of legally-exempted rebate kickbacks paid to PBMs. The good news is thanks to a series of actions by a number of different parties, the insulin PBM rebate price bubble finally burst whenLilly, followed byNovo Nordisk and thenSa...
Source: Scott's Web Log - June 11, 2023 Category: Endocrinology Tags: 2023 Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain report The Capitol Forum Source Type: blogs
After a Quiet Summer, Congress Starts Probe into MS Drugs
Congress has recently taken a few months off from constantly barraging the pharmaceutical industry with daily probes and negative news. However, on Thursday, August 17, 2017, Representatives Elijah Cummings of Maryland and Peter Welch of Vermont announced a probe into multiple sclerosis (MS) drug costs, focusing on pricing from seven different pharmaceutical companies, starting with letters to those companies.
Cummings and Welch are asking Bayer, Biogen, Serono (Merck KGaA), Novartis, Sanofi, Teva, and Roche for details about their pricing, focusing on the reasons behind price increases over the past several years. Teva l...
Source: Policy and Medicine - August 30, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
R & D Costs For Pharmaceutical Companies Do Not Explain Elevated US Drug Prices
That pharmaceutical companies charge much more for their drugs in the United States than they do in other Western countries has contributed to public and political distrust of their pricing practices. When these higher US prices (which are sometimes cited as being two to five times the prices in Europe) are challenged, the pharmaceutical industry often explains that the higher prices they charge in the US provide them with the funds they need to conduct their high-risk research.
This claim—that premiums earned from charging US patients and taxpayers more for medications than other Western countries funds companies’...
Source: Health Affairs Blog - March 7, 2017 Category: Health Management Authors: Nancy Yu, Zachary Helms and Peter Bach Tags: Costs and Spending Drugs and Medical Innovation Payment Policy Big Pharma drug pricing Source Type: blogs
Teva Pharmaceutical to Pay $519 Million to Settle FCPA Charges
Conclusion
The Criminal Division’s Fraud Section reached the resolution based on a variety of factors, including that Teva did not timely voluntarily self-disclose the conduct, but did cooperate with the department’s investigation after the SEC served it with a subpoena. Teva received a twenty percent discount off the low end of the United States Sentencing Guidelines fine range because of substantial cooperation and remediation. The company did not receive full cooperation credit, because, according to the DOJ, there were several issues that resulted in delays in the early stages of the investigation, including vast...
Source: Policy and Medicine - December 26, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
IMS Releases 2016 Report on Prescription Drug Spending – Net Price Growth 2.8% in 2015
Discussion on Medicare Part B Drug Payment Model Demonstration (Source: Policy and Medicine)
Source: Policy and Medicine - May 1, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Teva Pharmaceuticals v. Sandoz: Supreme Court Sides with Teva in Patent Case, Holds That Appeals Court Must Review Factual Findings Underlying Claim Construction for "Clear Error"
The Supreme Court on Tuesday handed down an important decision regarding how patent claims are handled on appeal. The U.S. Court of Appeals for the Federal Circuit hears every patent appeal in the country. Until yesterday, the Federal Circuit gave no weight to a trial judge’s interpretation regardless of whether the district court had heard factual evidence outside of the patent documents themselves. In legal terms, the Federal Circuit reviewed every issue of claim construction de novo. Since the appeal gave no deference to the lower court, the Federal Circuit had an extraordinary amount of control over one ...
Source: Policy and Medicine - January 22, 2015 Category: American Health Authors: Thomas Sullivan Source Type: blogs
What Happens When Governments Say MS Drugs Are Too Pricey?
I’m stuck on this one.
In recent days, the UK’s National Institute for Clinical Excellence (NICE) has decided not to widen use of beta-interferon for MS, and the Irish National Centre for Pharmaeconomics (NCPE) has refused to pay for the oral MS drug Tecfidera.
Interesting as well (and I’m not sure exactly how to think of this either) is that the US Supreme Court just made an MS drug ruling too, on Copaxone. This one seems to go the opposite way from the two European decisions.
My first thought is that every person living with multiple sclerosis must be given access to the drugs they and their medical team thi...
Source: Life with MS - January 21, 2015 Category: Other Conditions Authors: Trevis Gleason Tags: multiple sclerosis MS Around the Globe MS in the news MS Money Matters MS treatment Source Type: blogs
DOJ Subpoenas Teva in Marketing Probe
Teva Pharmaceutical Industries Ltd. TEVA.TV +1.85% said it received a subpoena from the Justice Department seeking information related to the sales and marketing of its Copaxone multiple sclerosis drug and its Azilect Parkinson's disease treatment.Teva said the government is looking into possible violations of the federal False Claims Act and is seeking information dating back to the beginning of 2006. The company also said it is in the process of complying with the subpoena but didn't give further details in its filing with the U.S. Securities and Exchange Commission.Copaxone is Teva's top-selling drug and is expect...
Source: PharmaGossip - February 10, 2014 Category: Pharma Commentators Authors: insider Source Type: blogs
Taking Copaxone? Expect a Call in the Coming Weeks
First and foremost let me say how much I absolutely abhor getting my MS pharmaceutical information via business and investment news flashes. Such was the case when I typed “FDA Copaxone formulation” into my search engine this morning.
The first full page of results was from investment sites, business analysis reviews, and pharma industry pages. I’ve grown used to getting much of my MS drug news from such sources, but today was the straw that broke this camel with MS’s back.
First, huzzah! People living with MS now have another choice in medication dosing. Particularly good for patients who hate needles is this ...
Source: Life with MS - January 31, 2014 Category: Other Conditions Authors: Trevis Gleason Tags: MS multiple sclerosis drug trial MS in the news MS treatment multiple sclerosis clinical trials New Products Source Type: blogs
What Copaxone Profits? Yet Another Troubling Leak At Teva
Yet another leak is plaguing Teva Pharmaceuticals. This time, the drugmaker is chafing over a report in an Israeli business publication called The Marker that published an internal, five-year forecast showing that profits from its all-important Copaxone multiple sclerosis drug will drop 42 percent in 2014.
Teva issued a statement maintaining the numbers were from an “outdated presentation” that is “incomplete and does not reflect our full analysis.” The drugmaker “is extremely disappointed that confidential, potentially misleading and obsolete information was made public at this time and intends to investigate ...
Source: Pharmalot - November 25, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and how are you today? We are doing just fine, thank you. After all, a shiny sun is warming the chilly Pharmalot corporate campus, where the short people are, as usual, hustling off to their houses of learning and the official mascots are, as always, barking at passersby. As for us, we are busy conducting our own version of R&D and brewing yet another cup of stimulation to help the process along. Feel free to grab a cup of something stimulating yourself. Meanwhile, here is the usual menu of tidbits. Hope you accomplish much today and do stay in touch...
Aurobindo Suffers A Fire At Manufacturing Facilit...
Source: Pharmalot - November 14, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Rise and shine, everyone, another busy day is on the way. The Pharmalot corporate campus has been buzzing with activity as the short people hustle off to their respective schoolhouses and the official mascots frolic among the weeds and leaves blanketing the grounds. As for us, we are sorting out the to-do list for the day, and it is a long list. We suspect that you can relate. So no time to dally. Let us all quaffe a cup of stimulation together and peruse the tidbits. Have a smashing day and keep us in mind if you hear something intriguing...
Novartis To Close UK Plant That Employs 400 Workers (West Sussex County Times)
Im...
Source: Pharmalot - November 5, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Teva CEO Resigns Amid Dispute With The Board; Who Will Take The Job?
Amid reported clashes with the board and accelerated plans to cut $2 billion in expenses, Teva Pharmaceuticals ceo Jeremy Levin has resigned and will be replaced by executive vp and chief financial officer Eyal Desheh on an interim basis. The move comes just two days after Levin emphatically refuted reports that he had threatened to resign and branded such talk as “rumors” and an “invention.”
His departure lays bare simmering disagreements – notably, with Teva chairman Phillip Frost - about the tactics needed to redirect the drugmaker, which is undergoing a large-scale reorganization that includes cutting 5,000 j...
Source: Pharmalot - October 30, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Amid Dispute With The Board, Teva CEO Denies He May Resign
Is there a dispute between the Teva Pharmaceuticals management and the board over day-to-day involvement? And did Teva ceo Jeremy Levin really threaten to resign? This is the buzz created by an Israeli television report that the Teva Executive Committee sent a letter urging the board to back off. This was followed by a denial that Levin considered resigning.
The hubbub comes two weeks after Teva accelerated a $2 billion reorganization by eliminating 10 percent of its global workforce, or 5,000 jobs, including about 800 in Israel, where the drugmaker is based (back story). Three months ago, a US court invalidated the 2015 p...
Source: Pharmalot - October 28, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
